The financing round saw participation from other new investors Pavilion Capital, Section 32, Invus and LifeSci Venture Partners. All of the Series A investors of Moma including Third
The post Moma Therapeutics completes funding for precision oncology programmes appeared first on Pharmaceutical Business review.